Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$MNKD Q1 '25 Earnings Results & Recap MannKind Corp. reported Q1 2025 EPS of $0.04, met estimates for $0.04, and revenue of $78 million, came in above the $76.02 million estimate; key outlooks include strong growth in the endocrine business, ongoing commercialization of Afrezza, and significant revenue potential from the pediatric Afrezza indication and the Tyvaso DPI collaboration.
1
3

Since Post

Full Details
amsteliam
Lies. Revenue was reported at 78 million.
3

Advertisement|Remove ads.